drugset / Trial / NCT00257452
A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)
RandomizedCrossoverDouble-blindTreatment
Summary
To demonstrate that tiotropium (Spiriva®) does not prolong the QT interval of the ECG more than placebo
Timeline
- Start
- 2004-10
- Primary completion
- 2005-07
- Completion
- 2005-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Moxifloxacin | Small molecule | 200 mg | — |
| Subject | Tiotropium | Other / unclassified | 18 ug | Inhaled |
| Subject | Tiotropium | Other / unclassified | 54 ug | Inhaled |
Indications
No indication recorded.